order final cut pro purchase windows 7 oem license buy quicken 2006 price of ms office 2013 professional buy office student and home 2010 cost of adobe acrobat 9 buy adobe elements 8 buy adobe acrobat professional 9 upgrade cheap microsoft office publisher 2003 used outlooks for sale cheap adobe cs4 design premium cheap photoshop 8 buy microsoft office 2010 pro cheap windows xp home upgrade order microsoft works 9 student discount windows 7 for 30 cheapest microsoft outlook 2003 buy indesign 2.0 buy 2007 access eset smart security purchase buy ms visio 2010 adobe contribute cs4 mac price cheap acronis true image home discount paperport software cheapest rosetta stone software discount microsoft access 2003 software discount windows xp sp3 outlook 2003 price buying adobe audition 3.0 buy cs3 photoshop

Cancer drug resistance strategy uncovered

Fri, Sep 9, 2011

Oral Cancer News

Source: Cancer Research UK
Author: Staff

 

Friday 9 September 2011-

US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance.

Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying why some patients only experience short-term benefits with cetuximab, or none at all.

Cetuximab is an antibody that interferes with cancer cell growth. It can be given in combination with chemotherapy to patients with bowel cancer or head and neck cancer.

Until now, scientists didn’t know why some cancers failed to respond to the drug, or initially responded but then became resistant.

The new study, published in Science Translational Medicine, found that in some of the drug-resistant cells, a protein known as ErbB2 (also known as HER2/neu) was sending ‘grow’ signals.

These were bypassing the ‘stop growing’ signals caused by the drug.

Pasi Janne, the study’s co-senior author, said: “ErbB2 activates a critical signalling pathway that is not normally blocked by cetuximab, and in this way subverts cetuximab’s function.

“Because ErbB2 isn’t affected by cetuximab, this is an easy way for cancers to become resistant to the drug.”

The researchers suggest that combining cetuximab with already available ErbB2 inhibitors such as trastuzumab (Herceptin) could produce an effective therapy to tackle cancers that previously showed resistance to cetuximab.

Henry Scowcroft, science information manager at Cancer Research UK, said: “Unfortunately, patients’s tumours can become resistant to treatment, and understanding why this happens is a major challenge in cancer research.

“This new study is a great example of how researchers are uncovering the molecular tricks cancer cells use to evade treatment, and finding out how to stop them doing so.

“Research like this gives us tremendous optimism that we’re on the cusp of a real revolution in cancer, although there’s a lot more work to do to make this a reality.”

Copyright Press Association 2011

Print Friendly
Be Sociable, Share!
, , , ,

Leave a Reply

You must be logged in to post a comment.